PL1990410T3 - Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D - Google Patents

Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D

Info

Publication number
PL1990410T3
PL1990410T3 PL07714709T PL07714709T PL1990410T3 PL 1990410 T3 PL1990410 T3 PL 1990410T3 PL 07714709 T PL07714709 T PL 07714709T PL 07714709 T PL07714709 T PL 07714709T PL 1990410 T3 PL1990410 T3 PL 1990410T3
Authority
PL
Poland
Prior art keywords
cd1d
immunotherapy
pulsed
target antigen
cell capable
Prior art date
Application number
PL07714709T
Other languages
English (en)
Inventor
Shin-Ichiro Fujii
Kanako Shimizu
Original Assignee
Riken
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken filed Critical Riken
Publication of PL1990410T3 publication Critical patent/PL1990410T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07714709T 2006-02-22 2007-02-21 Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D PL1990410T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006045193 2006-02-22
PCT/JP2007/053209 WO2007097370A1 (ja) 2006-02-22 2007-02-21 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
EP07714709.8A EP1990410B1 (en) 2006-02-22 2007-02-21 IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND

Publications (1)

Publication Number Publication Date
PL1990410T3 true PL1990410T3 (pl) 2020-07-13

Family

ID=38437409

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07714709T PL1990410T3 (pl) 2006-02-22 2007-02-21 Immunoterapia komórkami zdolnymi do ekspresji antygenu docelowego i CD1D oraz pulsowanymi ligandem CD1D

Country Status (12)

Country Link
US (1) US20100233215A1 (pl)
EP (2) EP1990410B1 (pl)
JP (2) JP5672647B2 (pl)
CY (1) CY1122911T1 (pl)
DK (1) DK1990410T3 (pl)
ES (2) ES2774707T3 (pl)
HU (1) HUE049283T2 (pl)
LT (1) LT1990410T (pl)
PL (1) PL1990410T3 (pl)
PT (1) PT1990410T (pl)
SI (1) SI1990410T1 (pl)
WO (1) WO2007097370A1 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5428010B2 (ja) * 2005-06-17 2014-02-26 独立行政法人理化学研究所 Ｎｋｔ細胞の機能解析法
US20100233215A1 (en) * 2006-02-22 2010-09-16 Riken IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
EP2199793A4 (en) * 2007-09-10 2012-01-11 Riken METHOD FOR EVALUATING HUMAN DENDRITIC CELLS AND IMMUNOTHERAPEUTIC AGENT FOR HUMAN CELLS
KR100995340B1 (ko) * 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
JPWO2010061930A1 (ja) 2008-11-28 2012-04-26 独立行政法人理化学研究所 ＣＤ１ｄ及び標的抗原の共発現アロ細胞を用いた免疫療法
US10316332B2 (en) 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
EP3231864A4 (en) * 2014-12-11 2018-05-30 Riken Modified immunocyte, method for producing modified immunocyte and utilization thereof
JP6743051B2 (ja) * 2015-01-27 2020-08-19 ラヴァ・セラピューティクス・ベー・フェー Ｃｄ１ｄを標的とする単一ドメイン抗体
JP7125760B2 (ja) * 2019-06-14 2022-08-25 国立研究開発法人理化学研究所 免疫系を賦活化する細胞および当該細胞を含む医薬組成物
US20220296705A1 (en) 2019-08-09 2022-09-22 Riken Combined use of artificial adjuvant vector cells and an immunostimulant
IL293483A (en) 2019-12-02 2022-08-01 Astellas Pharma Inc Cells used as an artificial adjuvant agent (aavcs), preparations containing them and their uses for cancer treatment
AR120648A1 (es) * 2019-12-02 2022-03-09 Astellas Pharma Inc Célula vector adyuvante artificial con contenido de ny-eso-1 para usar en el tratamiento del cáncer
JP2023078487A (ja) * 2020-04-08 2023-06-07 アステラス製薬株式会社 がんの処置に用いるｐｐ６５含有人工アジュバントベクター細胞
CN117480248A (zh) 2021-04-30 2024-01-30 国立研究开发法人理化学研究所 诱发针对冠状病毒的免疫应答的人工佐剂载体细胞和包含该细胞的药物组合物以及它们的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519521T2 (de) 1994-10-03 2001-06-28 Us Gov Nat Inst Health Zusammensetzung enthaltend ein antigen exprimierendes rekombinantes virus und ein immunstimulierendes molekül exprimierendes rekombinantes virus
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
JP2002112780A (ja) 2000-10-03 2002-04-16 Keio Gijuku ヒト膀胱癌抗原
JP2004147649A (ja) 2002-10-11 2004-05-27 Kumamoto Technology & Industry Foundation 頭頚部癌の抗原
HU0301358D0 (en) * 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
JP2005139118A (ja) 2003-11-07 2005-06-02 Ortho Mcneil Pharmaceut Inc 腫瘍の治療のための細胞治療方法
JP5002915B2 (ja) 2004-07-01 2012-08-15 住友化学株式会社 光学活性なシクロプロパンカルボン酸エステル化合物の製造方法およびそれに用いる不斉銅錯体
WO2007043630A1 (ja) * 2005-10-06 2007-04-19 Riken 上気道粘膜下に投与されるｎｋｔ細胞刺激剤
US20100233215A1 (en) * 2006-02-22 2010-09-16 Riken IMMUNOTHERAPY BY USING CELL CAPABLE OF CO-EXPRESSING TARGET ANTIGEN AND CD1d AND PULSED WITH CD1d LIGAND
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product
IL293483A (en) * 2019-12-02 2022-08-01 Astellas Pharma Inc Cells used as an artificial adjuvant agent (aavcs), preparations containing them and their uses for cancer treatment

Also Published As

Publication number Publication date
EP2441468A2 (en) 2012-04-18
JP2013212107A (ja) 2013-10-17
EP1990410A4 (en) 2009-08-26
EP1990410A1 (en) 2008-11-12
CY1122911T1 (el) 2021-10-29
DK1990410T3 (da) 2020-04-06
US20100233215A1 (en) 2010-09-16
JPWO2007097370A1 (ja) 2009-07-16
WO2007097370A1 (ja) 2007-08-30
SI1990410T1 (sl) 2020-07-31
ES2774707T3 (es) 2020-07-22
EP2441468A3 (en) 2012-10-17
LT1990410T (lt) 2020-03-10
JP5673723B2 (ja) 2015-02-18
EP2441468B1 (en) 2020-01-08
EP1990410B1 (en) 2020-01-08
ES2780176T3 (es) 2020-08-24
HUE049283T2 (hu) 2020-09-28
JP5672647B2 (ja) 2015-02-18
PT1990410T (pt) 2020-03-03

Similar Documents

Publication Publication Date Title
EP1990410A4 (en) IMMUNOTHERAPY THROUGH THE USE OF A CELL CAPABLE OF CO-EXPRESSING A TARGETED ANTIGEN AND CD1d AND PULSED BY A CD1D LIGAND
HK1248523A1 (zh) 用電穿孔向細胞負載抗原
AU2011255870A8 (en) Anti-human TROP-2 antibody having antitumor activity in vivo
IL238045A0 (en) Tumor treatment with an antibody against vegf
EP2396117B8 (fr) Procede et systeme de valorisation de materiaux et/ou produits par puissance pulsee
GB201207521D0 (en) Nput/output architechture for mounted processors, and methods of using same
ZA200808128B (en) Anti-tumor cell antigen antibody therapeutics
EP2409832A4 (en) DECORATIVE FILM WITH RADIO WAVE EMISSION AND DECORATIVE ELEMENT USING THE SAME
EP2203746A4 (en) SUB-POPULATIONS OF LYMPHOCYTES T CAPABLE OF TREATING CANCER
EP1937309A4 (en) CD8 + T LYMPHOCYTES REGULATORS INDUCED BY ANTI-CD3 ANTIBODIES
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
IL208167A0 (en) Method for detection of liver cancer cell using anti-glypican - 3 antibody
EP2229451A4 (en) MATERIALS AND METHOD FOR INHIBITING ANIMALS S NITROSOGLUTATHION REDUCTASE
EP2038402A4 (en) DEVICES AND METHODS FOR CRYOPRESERVATION OF CELLS
IL207958A0 (en) Allogeneic cancer cell - based immunotherapy
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
EP2371945A4 (en) IMMUNOTHERAPY PROCEDURE WITH CD1d AND TARGETANT CO-EXPRESSIVE ALLO CELLS
WO2010054377A3 (en) Fully human antibodies against n-cadherin
EP1773883A4 (en) PRODUCTION OF ANTICANCER ANTIBODIES USING MASKED CANCER CELLS AS IMMUNOGENS
EP1755626A4 (en) USES OF BISPECIFIC ANTIBODIES (BIAB) COATED DENDRITIC CELLS WITH ANY OTHER PULSE
EP2607879A4 (en) Microtome and cryostat
GB2448589B (en) High Altitude structures and related methods
WO2009076317A3 (en) Activated t cells
EP2689035A4 (en) METHOD AND KIT FOR THE IN VITRO DETERMINATION OF THE PROBABILITY OF SUFFERING A PATIENT AT A COLORECTAL CARCINOMA
WO2009120039A3 (en) Use of cd9 for a target protein to develop anticancer drug of solid cancers that overexpress cd9